Samoa Wellness Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Samoa Wellness Report.

Press releases published on August 11, 2026

Aug. 11, 2026

Gibson Oncology Announces First Patient Completes Initial Treatment Cycle in Phase II Trial of LMP744 for Recurrent Glioblastoma

Indeterminate GlobeNewswire

Aug. 11, 2026

Aqua-Tots Opens First Québec Location, Expanding Access to Swim Lessons in Île-Perrot

Indeterminate GlobeNewswire

Aug. 11, 2026

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Indeterminate GlobeNewswire

Aug. 11, 2026

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire

Aug. 11, 2026

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Indeterminate GlobeNewswire

Aug. 11, 2026

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

Indeterminate GlobeNewswire

Aug. 11, 2026

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

Indeterminate GlobeNewswire

Aug. 11, 2026

Frishantic Introduces New Magnesium Complex for Women, Combining Seven Magnesium Forms with L-Theanine and Vitamin B6

Indeterminate GlobeNewswire

Aug. 11, 2026

Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders

Indeterminate GlobeNewswire

Aug. 11, 2026

 Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or…

Indeterminate GlobeNewswire

Aug. 11, 2026

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Indeterminate GlobeNewswire

Aug. 11, 2026

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

Indeterminate GlobeNewswire

Aug. 11, 2026

Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States

Indeterminate GlobeNewswire

Aug. 11, 2026

Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Indeterminate GlobeNewswire

Aug. 11, 2026

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

Indeterminate GlobeNewswire

Aug. 11, 2026

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Indeterminate GlobeNewswire

Aug. 11, 2026

Constant Therapy Health Launches Web Platform for Speech, Language, and Cognitive Therapy

Indeterminate GlobeNewswire

Aug. 11, 2026

NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth

Indeterminate GlobeNewswire

Aug. 11, 2026

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire

Aug. 11, 2026

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Indeterminate GlobeNewswire